common.study.topics.clinical

Contrast Ultrasound Detection of Sentinel Lymph Nodes

common.study.values.description

Contrast Ultrasound Detection of Sentinel Lymph Nodes

This is a two part, open label, non-randomized trial of women with a breast cancer diagnosis scheduled for excisional surgery and sentinel lymph node (SLN) evaluation. Part 1 is a two-period, crossover, dose-finding study, which will be performed in 12 healthy female volunteers to determine the optimal dose as well as the safety and tolerability of the tissue-specific, contrast agent Sonazoid (GE Healthcare, Oslo, Norway) for human lymphatic applications. In Part 2 lymphosonographic SLN identification will be compared to that of isotope mapping during surgery on 90 female, breast cancer patients.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Sonazoid; Perflubutane for Injection

subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)

participant.views.study.view.additional

participant.views.study.view.scientific-title

Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients

common.study.values.clinical-trial-id

NCT02652923

participant.views.study.view.id

RdGW5d